Publications
324 results found
Monaghan TM, Biswas RN, Nashine RR, et al., 2021, Multiomics Profiling Reveals Signatures of Dysmetabolism in Urban Populations in Central India, Microorganisms, Vol: 9, Pages: 1485-1485
<jats:p>Background: Non-communicable diseases (NCDs) have become a major cause of morbidity and mortality in India. Perturbation of host–microbiome interactions may be a key mechanism by which lifestyle-related risk factors such as tobacco use, alcohol consumption, and physical inactivity may influence metabolic health. There is an urgent need to identify relevant dysmetabolic traits for predicting risk of metabolic disorders, such as diabetes, among susceptible Asian Indians where NCDs are a growing epidemic. Methods: Here, we report the first in-depth phenotypic study in which we prospectively enrolled 218 adults from urban and rural areas of Central India and used multiomic profiling to identify relationships between microbial taxa and circulating biomarkers of cardiometabolic risk. Assays included fecal microbiota analysis by 16S ribosomal RNA gene amplicon sequencing, quantification of serum short chain fatty acids by gas chromatography-mass spectrometry, and multiplex assaying of serum diabetic proteins, cytokines, chemokines, and multi-isotype antibodies. Sera was also analysed for N-glycans and immunoglobulin G Fc N-glycopeptides. Results: Multiple hallmarks of dysmetabolism were identified in urbanites and young overweight adults, the majority of whom did not have a known diagnosis of diabetes. Association analyses revealed several host–microbe and metabolic associations. Conclusions: Host–microbe and metabolic interactions are differentially shaped by body weight and geographic status in Central Indians. Further exploration of these links may help create a molecular-level map for estimating risk of developing metabolic disorders and designing early interventions.</jats:p>
Mullish BH, Ghani R, McDonald JAK, et al., 2021, Reply to Woodworth, et al., Clin Infect Dis, Vol: 72, Pages: e924-e925
Habboub N, Manousou P, Forlano R, et al., 2021, Metabolic Profiling of NASH Patients and Healthy Controls to Investigate the Transferability of a Healthy Metabolome Using Faecal Microbiota Transplantation, Metabolomics 2021
Smith PJ, 2021, GI highlights from the literature, Gut, Vol: 70, Pages: 1194-1195, ISSN: 0017-5749
Miguens Blanco J, Liu Z, Mullish BH, et al., 2021, A Phenomic Characterization of the Gut Microbiota - Associations with Psoriatic Arthritis and Ankylosing Spondylitis, World Microbe Forum
Barker GF, Pechlivanis A, Bello AT, et al., 2021, Aa022 a high-fiber low-fat diet increases fecal levels of lithocholic acid derivative 3-ketocholanic acid, Digestive Disease Week, Publisher: W B SAUNDERS CO-ELSEVIER INC, Pages: S393-S394, ISSN: 0016-5085
Mullish BH, Innes AJ, Ghani R, et al., 2021, FECAL MICROBIOTA TRANSPLANT PRIOR TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN PATIENTS COLONIZED WITH MULTI-DRUG RESISTANT ORGANISMS IS ASSOCIATED WITH IMPROVED SURVIVAL, Society-for-Surgery-of-the-Alimentary-Tract Annual Meeting at Digestive Disease Week (DDW), Publisher: W B SAUNDERS CO-ELSEVIER INC, Pages: S168-S169, ISSN: 0016-5085
Radhakrishnan ST, Mullish BH, Gallagher K, et al., 2021, RECTAL SWABS AS A VIABLE ALTERNATIVE TO FECAL SAMPLING FOR THE ANALYSIS OF GUT MICROBIOME FUNCTIONALITY AS WELL AS COMPOSITION, Society-for-Surgery-of-the-Alimentary-Tract Annual Meeting at Digestive Disease Week (DDW), Publisher: W B SAUNDERS CO-ELSEVIER INC, Pages: S733-S733, ISSN: 0016-5085
Mullish BH, Marchesi J, Pass DA, et al., 2021, DAILY PROBIOTIC USE IS ASSOCIATED WITH A REDUCED RATE OF UPPER RESPIRATORY TRACT SYMPTOMS IN OVERWEIGHT AND OBESE PEOPLE, Society-for-Surgery-of-the-Alimentary-Tract Annual Meeting at Digestive Disease Week (DDW), Publisher: W B SAUNDERS CO-ELSEVIER INC, Pages: S150-S150, ISSN: 0016-5085
Allegretti JR, Mullish BH, Marchesi J, et al., 2021, ASSOCIATION BETWEEN NOVEL METABOLOMIC BIOMARKERS AND C.DIFFICILE RECURRENCE, Society-for-Surgery-of-the-Alimentary-Tract Annual Meeting at Digestive Disease Week (DDW), Publisher: W B SAUNDERS CO-ELSEVIER INC, Pages: S369-S369, ISSN: 0016-5085
Martinez-Gili L, Mullish BH, Correia G, et al., 2021, A distinctive signature of fecal bile acids and other novel metabolites accompanying recurrence after primary clostridioides difficile infection, Society for Surgery of the Alimentary Tract Annual Meeting at Digestive Disease Week (DDW), Publisher: Elsevier, Pages: S368-S368, ISSN: 0016-5085
Ghani R, Mullish BH, McDonald JAK, et al., 2021, Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant Organisms, Clinical Infectious Diseases, Vol: 72, Pages: 1444-1447, ISSN: 1058-4838
<jats:title>Abstract</jats:title> <jats:p>Fecal microbiota transplantation (FMT) yields variable intestinal decolonization results for multidrug-resistant organisms (MDROs). This study showed significant reductions in antibiotic duration, bacteremia, and length of stay in 20 patients colonized/infected with MDRO receiving FMT (compared with pre-FMT history, and a matched group not receiving FMT), despite modest decolonization rates.</jats:p>
Mullish BH, Alexander JL, Segal JP, 2021, Microbiota and faecal microbiota transplant, Microbiota in Health and Disease, Vol: 3, ISSN: 2704-8845
As the range of disease states associated with the gut microbiome expands - and the mechanistic links between the gut microbiome and host physiology further deepens – so interest also grows in microbiome manipulation as medical therapy. In particular, bolstered by its established role in recurrent C. difficile infection (and promising results in other conditions), faecal microbiota transplant (FMT) has remained of growing global focus. This article reviews the key FMT-based studies published between April 2020 - March 2021. While the COVID-19 pandemic was the dominant challenge of the year, important FMT trials of interest were published for patients with a range of different conditions. The emergence of ‘next generation’ microbiome therapeutics offers an additional perspective and new opportunities within the field.
Gupta S, Mullish BH, Allegretti JR, 2021, Fecal microbiota transplantation: the evolving risk landscape, American Journal of Gastroenterology, Vol: 116, Pages: 647-656, ISSN: 0002-9270
Fecal microbiota transplantation (FMT) has been recommended in clinical guidelines for the treatment for recurrent Clostridioides difficile infection (CDI). However, it is considered investigational by most regulatory agencies. As the adoption of FMT increased from a small group of CDI experts alone to more widespread use, there has been a corresponding increase in concern regarding potential risk. FMT is largely considered a safe procedure, though risks described range from mild gastrointestinal symptoms to serious infection. Currently, there is variability in how ‘FMT’ is characterized specifically with regards to testing approach, which, in turn, impacts the risk profile. This has been highlighted by the rare cases of multidrug-resistant organisms, Shiga toxin-producing E. coli and enteropathogenic E. coli recently reported, where these organisms were not screened. These cases have prompted additional screening mandates from the FDA, which has maintained its policy of enforcement discretion for the use of FMT for CDI not responding to standard therapy. Here, we examine the evolving risk landscape of FMT.
Ianiro G, Mullish BH, Hvas CL, et al., 2021, SARS-CoV-2 vaccines and donor recruitment for FMT, The Lancet Gastroenterology & Hepatology, Vol: 6, Pages: 264-266, ISSN: 2468-1253
Smith PJ, 2021, GI highlights from the literature, Gut, Vol: 70, Pages: 803-804, ISSN: 0017-5749
Cole A, Bashyam M, Nathwani R, et al., 2021, A study evaluating outcomes of cirrhotic patients managed virtually in a specialist liver cirrhosis service due to the COVID crisis, ILC 2021, Publisher: Elsevier, Pages: S534-S534, ISSN: 0168-8278
Forlano R, Mullish B, Yee M, et al., 2021, A prospective cohort study for the prevalence and screeningpolicy of NAFLD in patients with T2DM in primary care, ILC 2021, Publisher: Elsevier, Pages: S558-S559, ISSN: 0168-8278
Forlano R, Mullish B, Miguens Blanco J, et al., 2021, A serum metabolic fingerprint may predict advanced fibrosis due to NAFLD in a cohort of diabetic patients, ILC 2021, Publisher: Elsevier, Pages: S540-S540, ISSN: 0168-8278
Edwards L, Woodhouse C, Mullish BH, et al., 2021, Faecal microbiota transplantation improves intestinal barrier function and modulates mucosal IL-17 immunity in patients with advanced cirrhosis, ILC 2021, Publisher: Elsevier, Pages: S220-S221, ISSN: 0168-8278
Mullish BH, Marchesi JR, McDonald JAK, et al., 2021, Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?, Gut Microbes, Vol: 13, Pages: 1-9, ISSN: 1949-0976
Gut microbiome manipulation to alter the gut-lung axis may potentially protect humans against respiratory infections, and clinical trials of probiotics show promise in this regard in healthy adults and children. However, comparable studies are lacking in overweight/obese people, who have increased risks in particular of viral upper respiratory tract infections (URTI). This Addendum further analyses our recent placebo-controlled trial of probiotics in overweight/obese people (focused initially on weight loss) to investigate the impact of probiotics upon the occurrence of URTI symptoms. As well as undergoing loss of weight and improvement in certain metabolic parameters, study participants taking probiotics experienced a 27% reduction in URTI symptoms versus control, with those ≥45 years or BMI ≥30 kg/m2 experiencing greater reductions. This symptom reduction is apparent within 2 weeks of probiotic use. Gut microbiome diversity remained stable throughout the study in probiotic-treated participants. Our data provide support for further trials to assess the potential role of probiotics in preventing viral URTI (and possibly also COVID-19), particularly in overweight/obese people.
Forlano R, Harlow C, Mullish BH, et al., 2021, Binge Eating Disorder is associated with an unfavourable body mass composition in patients with Non-Alcoholic fatty liver disease, ILC 2021, Publisher: Elsevier, Pages: S537-S538, ISSN: 0168-8278
Gilca-Blanariu GE, Stefanescu G, Girleanu I, et al., 2021, Romanian National Guideline on Translating Fecal Microbiota Transplantation Applications related to Clostridioides difficile Infections into the Local Clinical Practice, Journal of Gastrointestinal and Liver Diseases, Vol: 30, Pages: 147-163, ISSN: 1841-8724
<jats:p>Fecal microbiota transplantation involves the infusion of intestinal microorganisms via the transfer of a stool from a healthy individual into a diseased individual, with the intent of restoring normal intestinal flora. Fecal transplant is proposed for the treatment of refractory Clostridioides difficile infection. At present, recurrent Clostridioides difficile infection is the only indication supported by solid scientific evidence. Regulations by healthcare authorities vary among different countries. Considering that Romania does not have an available national guideline to offer standardization, this paper aimed to create a national fecal microbiota transplantation guideline concerning indications, techniques and donor screening, developed by international and local scientific working groups.</jats:p>
Mullish BH, Quraishi MN, Segal JP, et al., 2021, The gut microbiome: what every gastroenterologist needs to know, Frontline Gastroenterology, Vol: 12, Pages: 118-127, ISSN: 2041-4137
<jats:p>The mucosal surfaces of the body are characterised by complex, specialised microbial communities, often referred to as the<jats:italic>microbiome</jats:italic>. However, only much more recently—with the development of technologies allowing exploration of the composition and functionality of these communities—has meaningful research in this area become feasible. Over the past few years, there has been rapid growth in interest in the gut microbiome in particular, and its potential contribution to gastrointestinal and liver disease. This interest has already extended beyond clinicians to pharmaceutical companies, medical regulators and other stakeholders, and is high profile among patients and the lay public in general. Such expansion of knowledge holds the intriguing potential for translation into novel diagnostics and therapeutics; however, being such a nascent field, there remain many uncertainties, unanswered questions and areas of debate.</jats:p>
Allegretti JR, Kassam Z, Hurtado J, et al., 2021, Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity, HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, Vol: 20, Pages: 209-211, ISSN: 1109-3099
- Author Web Link
- Cite
- Citations: 20
Ghani R, Mullish B, Innes A, et al., 2021, Faecal microbiota transplant (FMT) prior to allogeneic haematopoietic cell transplantation (HCT) in patients colonised with multidrug-resistant organisms (MDRO) results in improved survival, ECCMID
NICE, 2021, Faecal microbiota transplant for recurrent or refractory Clostridioides difficile infection, Medtech innovation briefing [MIB247]
Morgan A, Vander Broek C, 2021, Microbiome Strategic Roadmap, Publisher: KTN
Monaghan T, Russell L, Rosati E, et al., 2021, P307 FMT-associated alterations in the TCR repertoire of patients with severe or fulminant Clostridioides difficile infection, BSG Campus, Publisher: BMJ Publishing Group, Pages: A199-A200, ISSN: 0017-5749
Michael DR, Davies TS, Jack AA, et al., 2021, Daily supplementation with the Lab4P probiotic consortium induces significant weight loss in overweight adults, Scientific Reports, Vol: 11
<jats:title>Abstract</jats:title><jats:p>This 9-month randomised, parallel, double-blind, single-centre, placebo-controlled study (PROBE, ISRCTN18030882) assessed the impact of probiotic supplementation on bodyweight. Seventy overweight Bulgarian participants aged 45–65 years with BMI 25–29.9 kg/m<jats:sup>2</jats:sup> received a daily dose of the Lab4P probiotic comprising lactobacilli and bifidobacteria (50 billion cfu/day). Participants maintained their normal diet and lifestyle over the duration of the study. The primary outcome was change from baseline in body weight and secondary outcomes included changes in waist circumference, hip circumference and blood pressure. A significant between group decrease in body weight (3.16 kg, 95% CI 3.94, 2.38, <jats:italic>p</jats:italic> < 0.0001) was detected favouring the probiotic group. Supplementation also resulted in significant between group decreases in waist circumference (2.58 cm, 95% CI 3.23, 1.94, <jats:italic>p</jats:italic> < 0.0001) and hip circumference (2.66 cm, 95% CI 3.28, 2.05, <jats:italic>p</jats:italic> < 0.0001) but no changes in blood pressure were observed. These findings support the outcomes of a previous shorter-term Lab4P intervention study in overweight and obese participants (PROMAGEN, ISRCTN12562026). We conclude that Lab4P has consistent weight modulation capability in free-living overweight adults.</jats:p>
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.